Gangliozytisches Paragangliom – eine seltene Differenzialdiagnose eines submukösen duodenalen Tumors

Zusammenfassung

Wir berichten über einen 36-jährigen Patienten, bei dem im Rahmen der Abklärung einer oberen gastrointestinalen Blutung ein submuköser Tumor im Duodenum diagnostiziert wurde. Nach Ausschluss weiterer Tumormanifestationen erfolgte die komplette endoskopische Resektion. Histologisch fand sich ein hochdifferenziertes, gangliozytisches Paragangliom, eine äußerst seltene Form eines neuroendokrinen Tumors. Anhand des vorliegenden Artikels werden Epidemiologie, Diagnostik und Therapiemöglichkeiten dieser seltenen Tumorart diskutiert.

Abstract

We report on the case of a 36-year-old male patient who was found to have a submucosal duodenal tumour during the diagnostic work-up of gastrointestinal bleeding. After exclusion of other tumour manifestations complete endoscopic resection was performed. Histologically a gangliocytic paraganglioma was diagnosed, a very rare type of a duodenal neuroendocrine tumour. This case report discusses the epidemiology, diagnostic work-up and therapeutic options for this rare tumour type.

NET - neuroendokriner Tumor - gangliozytisches Paragangliom - endoskopische Resektion

NET - neuroendocrine tumors - gangliocytic paraganglioma - endoscopic resection

Literatur

• 1 Kloppel G, Perren A, Heitz P U. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification.  Ann N Y Acad Sci. 2004;  1014 13-27
• 2 Rindi G, Kloppel G, Couvelard A et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.  Virchows Arch. 2007;  451 757-762
• 3 Clark O H, Benson  3rd A B, Berlin J D et al. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors.  J Natl Compr Canc Netw. 2009;  7 712-747
• 4 Jensen R T, Rindi G, Arnold R et al. Well-differentiated duodenal tumor/carcinoma (excluding gastrinomas).  Neuroendocrinology. 2006;  84 165-172
• 5 Bilimoria K Y, Bentrem D J, Wayne J D et al. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years.  Ann Surg. 2009;  249 63-71
• 6 Modlin I M, Lye K D, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors.  Cancer. 2003;  97 934-959
• 7 Modlin I M, Sandor A. An analysis of 8305 cases of carcinoid tumors.  Cancer. 1997;  79 813-829
• 8 Modlin I M, Champaneria M C, Chan A K et al. A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress.  Am J Gastroenterol. 2007;  102 1464-1473
• 9 Modlin I M, Oberg K, Chung D C et al. Gastroenteropancreatic neuroendocrine tumours.  Lancet Oncol. 2008;  9 61-72
• 10 Yao J C, Hassan M, Phan A et al. One hundred years after „carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.  J Clin Oncol. 2008;  26 3063-3072
• 11 Hassan M M, Phan A, Li D et al. Risk factors associated with neuroendocrine tumors: A U. S.-based case-control study.  Int J Cancer. 2008;  123 867-873
• 12 Hoffmann K M, Furukawa M, Jensen R T. Duodenal neuroendocrine tumors: Classification, functional syndromes, diagnosis and medical treatment.  Best Pract Res Clin Gastroenterol. 2005;  19 675-697
• 13 Burke A P, Sobin L H, Federspiel B H et al. Carcinoid tumors of the duodenum. A clinicopathologic study of 99 cases.  Arch Pathol Lab Med. 1990;  114 700-704
• 14 Dahl E V, Waugh J M, Dahlin D C. Gastrointestinal ganglioneuromas; brief review with report of a duodenal ganglioneuroma.  Am J Pathol. 1957;  33 953-965
• 15 Taylor H B, Helwig E B. Benign nonchromaffin paragangliomas of the duodenum.  Virchows Arch Pathol Anat Physiol Klin Med. 1962;  335 356-366
• 16 Kepes J J, Zacharias D L. Gangliocytic paragangliomas of the duodenum. A report of two cases with light and electron microscopic examination.  Cancer. 1971;  27 61-67
• 17 Witkiewicz A, Galler A, Yeo C J et al. Gangliocytic paraganglioma: case report and review of the literature.  J Gastrointest Surg. 2007;  11 1351-1354
• 18 Nagai T, Torishima R, Nakashima H et al. Duodenal gangliocytic paraganglioma treated with endoscopic hemostasis and resection.  J Gastroenterol. 2004;  39 277-283
• 19 Fottner C, Helisch A, Anlauf M et al. 6 – 18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.  J Clin Endocrinol Metab. 2010;  95 2800-2810
• 20 Timmers H J, Chen C C, Carrasquillo J A et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.  J Clin Endocrinol Metab. 2009;  94 4757-4767
• 21 Jamali M, Chetty R. Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining.  Endocr Pathol. 2008;  19 282-288
• 22 Vilar E, Salazar R, Perez-Garcia J et al. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors.  Endocr Relat Cancer. 2007;  14 221-232
• 23 Schimke R N, Collins D L, Stolle C A. Paraganglioma, neuroblastoma, and a SDHB mutation: Resolution of a 30-year-old mystery.  Am J Med Genet A. 2010;  152A 1531-1535
• 24 Lodish M B, Adams K T, Huynh T T et al. Succinate dehydrogenase gene mutations are strongly associated with paraganglioma of the organ of Zuckerkandl.  Endocr Relat Cancer. 2010;  17 581-588
• 25 Rinke A, Muller H H, Schade-Brittinger C et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.  J Clin Oncol. 2009;  27 4656-4663
• 26 Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut.  Neuroendocrinology. 2009;  89 471-476
• 27 Sobin L H, Gospodarowicz M K, Wittekind C et al. UICC: TNM classification of malignant tumours. Oxford: Wiley-Blackwell. 7th edn